Intermap Technologies ("Intermap" or the "Company"), a global leader in 3D geospatial products and intelligence solutions, today announced 2024 results and 2025 guidance. For the full year ending ...

Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose ...

Scinai Immunotherapeutics Ltd. , a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and in providing CDMO services through its Scinai Bioservices unit, ...

Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development ...

Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to acceler ...

According to the American Cancer Society, approximately 1 in 8 men in the U.S. will be diagnosed with prostate cancer during their lifetime. In ...

Bioluminescent luciferase enzymes have historically been too dim to use as probes in living tissue. But recent advances have ...

Researchers develop innovative phospholipids that improve the functional delivery of mRNA via lipid nanoparticles, paving the ...

Cancer refers to a group of complicated diseases which is one of the top two leading causes of death globally. Traditional chemotherapy and radiation ...

A research team led by Dr. Li Yunhai from the Institute of Genetics and Developmental Biology of the Chinese Academy of ...

Scientists have long recognized the brain's need for energy, but new research from the University of Kentucky's Sanders-Brown ...

DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) announced 2024 results and listed a number of accomplishments that will bring both product and grant revenue in the next ...